New Perspectives on Overactive Bladder and Its Treatment

home / publications / supplement / a220_09mar_oab

C. Daniel Mullins, PhD

March 24th 2009

ArticleSUPPLEMENT CONTENT

Fesoterodine: A New Agent for Treating Overactive Bladder

Pamela Ellsworth, MD;Sandra J. Berriman, PhD;Marina Brodsky, PhD

March 24th 2009

ArticleSUPPLEMENT CONTENT

Pharmacotherapy Adherence and Costs Versus Nonpharmacologic Management in Overactive Bladder

Elise M. Pelletier, MS;Vasudha Vats, MPH;J. Quentin Clemens, MD, MSCI

March 24th 2009

ArticleSUPPLEMENT CONTENT

Challenges for Managing Overactive Bladder and Guidance for Patient Support

Vernon F. Schabert, PhD;Tamara Bavendam, MD;Erica L. Goldberg;Jeffrey N. Trocio, MPH;Linda Brubaker, MD

March 24th 2009

ArticleSUPPLEMENT CONTENT

Participating Faculty

March 24th 2009

ArticleSUPPLEMENT CONTENT

Impact of Overactive Bladder on Work Productivity in the United States: Results From EpiLUTS

Chris C. Sexton, PhD;Karin S. Coyne, PhD, MPH;Vasudha Vats, MPH;Zoe S. Kopp, PhD, MPH;Debra E. Irwin, MSPH, PhD;Todd H. Wagner, PhD

March 24th 2009

ArticleSUPPLEMENT CONTENT

The Total Economic Burden of Overactive Bladder in the United States: A Disease-Specific Approach

Ebere Onukwugha, PhD;Ilene H. Zuckerman, PharmD, PhD;Diane McNally, BSPharm, MS;Karin S. Coyne, PhD, MPH;Vasudha Vats, MPH;C. Daniel Mullins, PhD

March 24th 2009

ArticleSUPPLEMENT CONTENT

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions